Cytiva

[Not Yet Scheduled]
GE Healthcare Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With a focus on accelerating and advancing therapeutics from discovery to manufacture to use, the Life Sciences business is a global leader in the development of next generation biologics, vaccines and cell and gene therapies. The products and software developed and manufactured by GE Healthcare Life Sciences enables academics, start-ups, clinical-stage and established biotechnology companies to research, identify and manipulate genes, cells and proteins, to develop a deep understanding of how they work to then modify them into producing life altering therapeutics.

Simply put, GE Healthcare Life Sciences envisions a world where every person has access to safe and effective therapeutics that allows them to lead healthy lives.


Ticker:
GE
Exchange:
NYSE
Company Type:
Publicly Traded Company
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
N/A
Main Therapeutic Focus:
Lead Product in Development:
Cryopreservation tools to enable the delivery of cell therapies.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
N/A
Speaker
photo
Senior Communications Manager
GE Healthcare Life Sciences